Physician profile
James E Mossell
NPI 1720195837
$1,611,604.40
in general payments reported to CMS, 2019-2025
42 companies · $259K in 2025
The $259K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374K · 2020: $126K · 2021: $182K · 2022: $219K · 2023: $190K · 2024: $262K · 2025: $259K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $448K · Travel and Lodging: $151K · Consulting Fee: $45K · Honoraria: $43K · Food and Beverage: $24K · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $447,569.50 |
| Travel and Lodging | $150,709.56 |
| Consulting Fee | $44,657.08 |
| Honoraria | $43,287.50 |
| Food and Beverage | $24,233.10 |
| Education | $485.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $349,352.58 | 2019-2025 | Evenity, Otezla, Otezla |
| Abbvie INC. | $303,276.19 | 2019-2025 | |
| Horizon Therapeutics Plc | $217,422.12 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $178,070.74 | 2019-2025 | |
| Ucb, INC. | $146,553.32 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $95,742.69 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70,026.56 | 2020-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $59,290.91 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $49,710.81 | 2019 | |
| Celgene Corporation | $41,457.04 | 2019 | |
| Ani Pharmaceuticals, INC. | $32,590.89 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $24,701.03 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $15,348.49 | 2019-2025 | |
| Pfizer INC. | $9,997.43 | 2019-2025 | |
| Janssen Biotech, INC. | $7,126.11 | 2019-2025 | Tremfya, Simponi Aria |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $4,055.25 | 2019 | |
| Sobi, INC | $2,670.42 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $671.22 | 2022-2025 | Saphnelo, Evusheld |
| E.R. Squibb & Sons, L.L.C. | $599.59 | 2019-2025 | Orencia |
| Genentech USA, INC. | $507.14 | 2019-2025 | Actemra, Erivedge, Gazyva |
| Lilly USA, LLC | $424.10 | 2019-2024 | Taltz |
| Sanofi-Aventis U.S. LLC | $312.44 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $309.60 | 2019-2025 | Euflexxa |
| Radius Health, INC. | $301.37 | 2019-2025 | Tymlos |
| Grifols USA, LLC | $206.43 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $157.24 | 2024-2025 | Cuvitru |
| Fresenius Kabi USA, LLC | $97.30 | 2023-2025 | Tyenne |
| Csl Behring | $95.76 | 2022-2025 | Hizentra |
| Janssen Scientific Affairs, LLC | $82.22 | 2020-2022 | |
| Antares Pharma, INC. | $58.83 | 2019-2020 | |
| Depuy Synthes Sales INC. | $54.41 | 2019-2021 | |
| Octapharma USA, INC. | $51.83 | 2024-2025 | Octagam Immune Globulin (Human) |
| Pacira Therapeutics, INC. | $46.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $40.91 | 2025 | Tremfya |
| Scilex Pharmaceuticals INC. | $38.04 | 2024-2025 | |
| Medline Industries Lp | $35.31 | 2022 | |
| Tactile Systems Technology INC | $34.63 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.40 | 2021 | |
| Hikma Pharmaceuticals USA | $18.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.70 | 2024 | |
| Sandoz INC. | $14.39 | 2023 | Hyrimoz |
| Avion Pharmaceuticals | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mossell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.